The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status.

By Robert B. West, Christopher Corless, Xin Chen, B. Rubin, Subbaya Subramanian, K. Montgomery, Shirley X. Zhu, C. Ball, Torsten O. Nielsen, Rajiv M. Patel and 4 more. American Journal of Pathology, 2004

656 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Pathology of Peripheral Nerve Sheath Tumors: Diagnostic Overview and Update on Selected Diagnostic Problems (2012, positive): “DOG1 (‘‘discovered on GIST 1/Anoctamin-1’’) is a recently described membrane protein, a highly sensitive and specific marker for GIST, expressed even in tumors lacking KIT or PDGFRA mutations [52, 143].”
Expression cloning of TMEM16A as a calcium-activated chloride channel subunit (2008, background): “Modulators of CaCCs that control the volume of the airway surface liquid bathing the airway epithelial cilia, whose proper movement is crucial for mucus clearing, may also be considered for treating chronic obstructive pulmonary diseases like bronchitis and asthma (Tarran et al., 2006; Widdicombe, 2”
Gastrointestinal stromal tumours: origin and molecular oncology (2011, background): “In addition, both types of tumours are immunopositive for the markers discovered on GIST 1 (DOG1; also known as anoctamin 1) and protein kinase C-θ (PKCθ”
Handbook of ion channels (2015, background): “Under the names GIST-1 (DOG-1) (West et al., 2004), FLJ10261 and oral cancer overexpressed 2 (ORAOV2) (Katoh, 2003), and tumor-amplified and overexpressed sequence 2 (TAOS2) (Huang et al.”